Kent J. Johnson, MD

Dr. Johnson is a leading researcher in clinical and preclinical renal pathology and inflammation. His research programs in diabetic nephropathy, vasculitis, and cytokine regulation have been instrumental in supporting drug development at Pfizer, Warner-Lambert, Genentech, Quantum Immunologics, and Medicis. Dr. Johnson is a full professor in the Department of Pathology at the University of Michigan Medical School where he works with Dr. Varani on models of tumor development and metastasis. As a long-time consultant and collaborator with industry, Dr. Johnson has played a key role in advancing a broad spectrum of new pharmaceutical molecules. Dr. Johnson received his undergraduate degree from the University of North Dakota, and his medical degree from the University of Connecticut.

Gregory Landes, Ph.D.

Dr. Landes has over 30 years of experience in the biotechnology industry with broad expertise in target discovery and validation, antibody and ADC drug discovery and preclinical development, molecular biology, genetics, genomics, and biochemistry. He currently consults with over a dozen companies in the disciplines described above as well as automation, biosimilars and antibody effector function. In addition, he leads workshops at national antibody conferences in a variety of areas of expertise including antibody effector function and antibody drug conjugates. He has held positions of significant responsibility with major biopharmaceutical companies including Takeda California/Takeda San Francisco (VP Biology/VP Discovery, Research and Preclinical Development, Lexicon Pharmaceuticals (VP, Biotherapeutics), Abgenix (VP, Product Discovery), Genzyme (VP, Genetics and Genomics), and Integrated Genetics (Senior Scientist, Genetics and DNA Diagnostics). He holds a BA in Chemistry and Ph.D. in Biochemistry from the University of Kansas and was awarded a post-doctoral scholarship from UCLA’s Molecular Biology Institute as well as an NIH post-doctoral award. Dr. Landes is a Biotechnology Consultant at DNA Bridges, and he is an adjunct professor at the University of Texas Southwestern Medical Center.

Curt Scribner, MD, MBA

Dr. Scribner is Senior Vice President of Medical and Regulatory Affairs at RRD International, LLC. Dr. Scribner is a board certified physician in internal medicine and has direct experience in developing and running small and large clinical programs. He joined RRD from Intarcia Therapeutics, where he was the Vice President of Regulatory and Quality Affairs and Chief Regulatory Officer. Previously, Dr. Scribner was Chief Regulatory Consultant for Quintiles Consulting, where he developed and wrote numerous NDA, BLA, IND, IDE, 510(k), PMA, and MAA applications. Prior to Quintiles Consulting, Dr. Scribner spent 10 years at FDA, where he held a variety of positions and was involved in reviewing products regulated by the Center for Biologics. Dr. Scribner holds an MD from the University of Colorado College of Medicine, an MBA from the University of Maryland College of Business and Management, and a BA in biology from Grinnell College.

James Varani, Ph.D.

Dr. Varani is an internationally recognized expert in human cell and organ culture, particularly models of skin. He has worked with major pharmaceutical and biotechnology companies, including Johnson and Johnson, Medicis, Genentech, Warner-Lambert, Pfizer, Quantum Immunologics, and Amgen. Utilizing in vitro and in vivo models he has supported retinoid, oncology, anti-inflammatory, and immunomodulatory drup programs. Dr. Varani is a full professor in the Department of Pathology at the University of Michigan Medical School. His experience and expertise in cell culture, organ culture, and animal models of disease have been the basis of multiple NIH, SBIR, and STTR programs addressing diseases. Dr. Varani received his undergraduate degree from St. John's University in Collegeville, Minnesota and his Ph.D. at the University of North Dakota.